Gilmore O’Neill, Editas Medicine CEO

Ed­i­tas re­ports ear­ly-stage da­ta from two pa­tients in sick­le cell dis­ease

One com­pa­ny is mov­ing for­ward in its bid to make a cell ther­a­py for sick­le cell dis­ease vi­able — and af­ter pre­vi­ous set­backs, in­clud­ing a hold …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.